Shortage of Bupivacaine Hydrochloride and Epinephrine Injection
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection, affecting various presentations due to delays in shipping and manufacturing issues.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection.
Shortage of Bupivacaine Hydrochloride and Epinephrine Injection
What's in Shortage
The generic drug name is Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection. Brand names include SENSORCAINE MPF, BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, MARCAINE WITH EPINEPHRINE, and SENSORCAINE. It is available in injection dosage form and is currently in shortage status. This medication belongs to the therapeutic category of Anesthesia. The shortage was first posted on 02/20/2018 and last updated on 04/02/2026.
Which Manufacturers Are Affected
- Fresenius Kabi USA, LLC: Some presentations are available, such as Sensorcaine Injection 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37), with advice to check wholesalers for inventory. Others are unavailable with expected recovery TBD. Contact: 888-386-1300.
- Hospira, Inc., a Pfizer Company: Several presentations are unavailable, such as Bupivacaine Hydrochloride and Epinephrine Injection 125 mg/50 mL (NDC 0409-9043-01), with next delivery and estimated recovery in December 2028 due to manufacturing delays. Some are available, like Marcaine With Epinephrine Injection 150 mg/30 mL (NDC 0409-1749-29). Contact: 844-646-4398.
Why There's a Shortage
The shortage is due to a delay in shipping of the drug. Some manufacturers have specified manufacturing delays as the reason.
What Patients Should Do
Patients who depend on this medication should talk to their pharmacist or healthcare provider to check availability and discuss options. They can contact the manufacturers directly for more details. Patients should consult their healthcare provider for any advice and not make changes without professional guidance.
Source
This information is from the FDA Drug Shortage Database, initially posted on 02/20/2018 and last updated on 04/02/2026.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,815 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.